Dr Chris Roberts appointed Non-Executive Director at Clarity Pharmaceuticals
ATP Innovations portfolio company Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Chris Roberts as an independent Non- Executive Director of the Company.
Dr Roberts has over 40 years’ experience in the medical innovation space and has served on the boards of a number of ASX listed companies as well as research institutions and government entities. He was Chief Executive Officer of Cochlear Limited (ASX: COH) for over 11 years and was Chairman of Sirtex Medical Ltd (ASX: SRX) from 2000 to 2002 including during its listing on the ASX. Dr Roberts was also Executive Vice-President of ResMed Inc (NYSE: RMD, ASX: RMD), a global sleep disorder treatment company, from 1992 to 2004. He is currently a Non- Executive Director of ResMed Inc. and Oncosil Ltd (ASX:OSL).
Dr Roberts is also actively involved in the non-commercial sector, sitting on the boards of such research institutions and government entities as Innovation Science Australia, Jobs for NSW, University of Technology Sydney Vice- Chancellor’s Industry Advisory Board, the University of New South Wales Faculty of Medicine Advisory Council, Monash University Industry Council of Advisors and the NHMRC’s Health Innovation Advisory Committee. Dr Roberts is a member of the Board of Governors of the Centenary Institute of Cancer Medicine and Cell Biology, and is an Honorary Fellow of the Australian Institute of Business and Economics at the University of Queensland. Dr Roberts is a PLuS Alliance Professor in biomedical engineering, an alliance of 3 universities: University of NSW, King’s College London, and Arizona State University.
Dr Roberts commented: “I am particularly excited to be joining the Clarity Board as the Company is stepping into a very important stage of its development and moves to progress its SARTATE Technology into a number of clinical trials. The opportunity to commercialise this innovative treatment and save lives of children with cancer is extremely motivating”.
Clarity is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally. Clarity’s platform technology allows drugs to be radio-labelled and visualised using PET imaging. The human imaging data generated provides information on whether the drug reaches the desired disease target in a patient. This information enables a personalised approach to therapy by only treating those patients that are likely to respond to therapy and excluding those that won’t respond to therapy. This precision medicine approach is at the forefront of drug development. Clarity utilises this expertise to develop its own clinical pipeline of products and also offers this capability as a service to biopharmaceutical developers worldwide.
Clarity’s Executive Chairman, Dr Alan Taylor, stated: “We are very excited to welcome Dr Roberts to our Board of Directors and are looking forward to working together as Clarity progresses with a number of thrilling opportunities in theranostic development. It is very rare to find someone with such an outstanding track record of successful achievements in the commercialisation and capital markets space and we believe Dr Roberts’ expertise will be invaluable in continuing to build Clarity’s story”.
Dr Roberts holds a BE (Honours) in Chemical Engineering from the University of New South Wales, an MBA from Macquarie University and a PhD from the University of New South Wales. He was awarded Honorary Doctor of Science degrees from Macquarie University and the University of New South Wales. He is a Fellow of the Academy of Technological Sciences and Engineering (FTSE), Fellow of the Australian Institute of Company Directors (FAICD) and Honorary Fellow of The Institution of Engineers Australia (FIEAust).
Clarity Pharmaceuticals is a personalised medicine company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally.